GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » Institutional Ownership

Cardiff Oncology (STU:XE7C) Institutional Ownership : 8.73% (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cardiff Oncology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cardiff Oncology's institutional ownership is 8.73%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cardiff Oncology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cardiff Oncology's Float Percentage Of Total Shares Outstanding is 97.17%.


Cardiff Oncology Institutional Ownership Historical Data

The historical data trend for Cardiff Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Institutional Ownership Chart

Cardiff Oncology Historical Data

The historical data trend for Cardiff Oncology can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 11.14 11.14 11.06 7.91 7.93 8.16 8.17 8.18 8.72 8.73

Cardiff Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cardiff Oncology (STU:XE7C) Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Cardiff Oncology (STU:XE7C) Headlines

No Headlines